Search

Your search keyword '"Solovic, Ivan"' showing total 4 results
Start Over Author "Solovic, Ivan" Topic imipenem
4 results on '"Solovic, Ivan"'

1. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Author

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, and Migliori GB

Subjects
Adult, Cohort Studies, Comparative Effectiveness Research, Drug Resistance, Bacterial, Female, Humans, Male, Meropenem, Middle Aged, Sputum metabolism, Time Factors, Treatment Outcome, Antitubercular Agents administration & dosage, Clavulanic Acid administration & dosage, Extensively Drug-Resistant Tuberculosis drug therapy, Imipenem administration & dosage, Thienamycins administration & dosage, Tuberculosis, Multidrug-Resistant drug therapy
Abstract

No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanate versus meropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases.84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60-428) versus 85 (49-156) days, respectively.Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only.Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients., (Copyright ©ERS 2016.)

Published
2016
Full Text
View/download PDF

2. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Author

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, and Migliori GB

Subjects
Drug Therapy, Combination, Humans, Treatment Outcome, Antitubercular Agents therapeutic use, Clavulanic Acid therapeutic use, Extensively Drug-Resistant Tuberculosis drug therapy, Imipenem therapeutic use
Published
2016
Full Text
View/download PDF

3. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Author

Fabrizio Palmieri, Aurora Jazmín Roby Arias, Alena Skrahina, Gina Gualano, Giovanni Sotgiu, Dante Vargas Vasquez, Eduardo Henrique Bonini, Marina Tadolini, Gerard de Vries, Saverio De Lorenzo, Jose A. Caminero, Pietro Viggiani, Marcos Abdo Arbex, Valentina Alarcon Guizado, Apostolos Papavasileiou, Lorena Collahuazo López, Simon Tiberi, Simone Dore, Andrea Piana, Anna Scardigli, Vera Auchynka, Marie-Christine Payen, Antonio Spanevello, Felix Antonio Chong Marin, Alena Aleksa, Edith Alarcon Arrascue, Janina Artsukevich, Heinke Kunst, Alberto Matteelli, Onno W. Akkerman, Giorgia Sulis, Alimuddin Zumla, Giovanni Battista Migliori, Lia D'Ambrosio, Ivan Solovic, Jan-Willem C. Alffenaar, Mina Gaga, Charalampos Moschos, Veronica White, Rosella Centis, Tiberi, Simon, Sotgiu, Giovanni, D'Ambrosio, Lia, Centis, Rosella, Arbex, Marcos Abdo, Arrascue, Edith Alarcon, Alffenaar, Jan Willem, Caminero, Jose A., Gaga, Mina, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Guizado, Valentina Alarcon, De Lorenzo, Saverio, Arias, Aurora Jazmín Roby, Scardigli, Anna, Akkerman, Onno W., Aleksa, Alena, Artsukevich, Janina, Auchynka, Vera, Bonini, Eduardo Henrique, Marín, Félix Antonio Chong, López, Lorena Collahuazo, De Vries, Gerard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Moschos, Charalampo, Palmieri, Fabrizio, Papavasileiou, Apostolo, Payen, Marie-Christine, Piana, Andrea, Spanevello, Antonio, Vasquez, Dante Varga, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Migliori, Giovanni Battista, and Microbes in Health and Disease (MHD)

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Imipenem, medicine.drug_class, DELAMANID, Antibiotics, Drug resistance, MULTIDRUG-RESISTANT, Meropenem, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, COMPASSIONATE USE, polycyclic compounds, Culture conversion, MEROPENEM-CLAVULANATE, Medicine, 030212 general & internal medicine, business.industry, Medicine (all), DRUG-RESISTANT TUBERCULOSIS, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, EFFICACY, BEDAQUILINE, Multiple drug resistance, 030228 respiratory system, Tolerability, TOLERABILITY, MYCOBACTERIUM-TUBERCULOSIS, Delamanid, business, LINEZOLID SAFETY, medicine.drug
Abstract

No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanateversusmeropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanateversusmeropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases.84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8versus8) but more fluoroquinolone resistance (79.0%versus48.9%, pversus49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60–428)versus85 (49–156) days, respectively.Statistically significant differences were observed on sputum smear and culture conversion rates (79.7%versus94.8%, p=0.02 and 71.9%versus94.8%, pversus77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only.Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients.

Published
2016

4. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

Author

Valentina Alarcon Guizado, Giovanni Sotgiu, Alberto Matteelli, Veronica White, Eduardo Henrique Bonini, Marina Tadolini, Mina Gaga, Saverio De Lorenzo, Fabrizio Palmieri, Lorena Collahuazo López, Aurora Jazmín Roby Arias, Rosella Centis, Ivan Solovic, Anna Scardigli, Edith Alarcon Arrascue, Alena Skrahina, Antonio Spanevello, Marie-Christine Payen, Heinke Kunst, Janina Artsukevich, Vera Avchinko, Apostolos Papavasileiou, Giorgia Sulis, Gerard de Vries, Pietro Viggiani, Charalampos Moschos, Lia D'Ambrosio, Onno W. Akkerman, Jan-Willem C. Alffenaar, Simone Dore, Dante Vargas Vasquez, Simon Tiberi, Alimuddin Zumla, Giovanni Battista Migliori, Andrea Piana, Alena Aleksa, Felix Antonio Chong Marin, Jose A. Caminero, Marcos Abdo Arbex, Gina Gualano, Microbes in Health and Disease (MHD), Tiberi, Simon, Sotgiu, Giovanni, D'Ambrosio, Lia, Centis, Rosella, Arbex, Marcos Abdo, Alarcon Arrascue, Edith, Alffenaar, Jan Willem, Caminero, Jose A., Gaga, Mina, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Alarcon Guizado, Valentina, De Lorenzo, Saverio, Roby Arias, Aurora Jazmín, Scardigli, Anna, Akkerman, Onno W., Aleksa, Alena, Artsukevich, Janina, Avchinko, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gerard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Moschos, Charalampo, Palmieri, Fabrizio, Papavasileiou, Apostolo, Payen, Marie Christine, Piana, Andrea, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, and Migliori, Giovanni Battista

Subjects
Infectious Diseases, Microbiology (medical), Medicine (all), Extensively Drug-Resistant Tuberculosis, Treatment outcome, Antitubercular Agents, Microbiology, Antitubercular Agent, 03 medical and health sciences, 0302 clinical medicine, Humans, Medicine, 030212 general & internal medicine, Clavulanic Acid, METAANALYSIS, OUTCOMES, business.industry, Imipenem, Treatment Outcome, TB, 030228 respiratory system, Extensively Drug-Resistant Tuberculosi, Drug Therapy, Combination, business, Humanities, Human
Abstract

Simon Tiberi, Giovanni Sotgiu, Lia D’Ambrosio, Rosella Centis, Marcos Abdo Arbex, Edith Alarcon Arrascue, Jan Willem Alffenaar, Jose A. Caminero, Mina Gaga, Gina Gualano, Alena Skrahina, Ivan Solovic, Giorgia Sulis, Marina Tadolini, Valentina Alarcon Guizado, Saverio De Lorenzo, Aurora Jazmin Roby Arias, Anna Scardigli, Onno W. Akkerman, Alena Aleksa, Janina Artsukevich, Vera Avchinko, Eduardo Henrique Bonini, Felix Antonio Chong Marin, Lorena Collahuazo Lopez, Gerard de Vries, Simone Dore, Heinke Kunst, Alberto Matteelli, Charalampos Moschos, Fabrizio Palmieri, Apostolos Papavasileiou, Marie-Christine Payen, Andrea Piana, Antonio Spanevello, Dante Vargas Vasquez, Pietro Viggiani, Veronica White, Alimuddin Zumla and Giovanni Battista Migliori

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results